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Abstract
Objective
To characterize the phenotypic spectrum, molecular genetic ﬁndings, and functional con-
sequences of pathogenic variants in early-onset KCNT1 epilepsy.
Methods
We identiﬁed a cohort of 31 patients with epilepsy of infancy with migrating focal seizures
(EIMFS) and screened for variants in KCNT1 using direct Sanger sequencing, a multiple-gene
next-generation sequencing panel, and whole-exome sequencing. Additional patients with non-
EIMFS early-onset epilepsy in whom we identiﬁed KCNT1 variants on local diagnostic multiple
gene panel testing were also included. When possible, we performed homology modeling to
predict the putative eﬀects of variants on protein structure and function. We undertook elec-
trophysiologic assessment of mutant KCNT1 channels in a xenopus oocyte model system.
Results
We identiﬁed pathogenic variants in KCNT1 in 12 patients, 4 of which are novel. Most variants
occurred de novo. Ten patients had a clinical diagnosis of EIMFS, and the other 2 presented with
early-onset severe nocturnal frontal lobe seizures. Three patients had a trial of quinidine with
good clinical response in 1 patient. Computational modeling analysis implicates abnormal pore
function (F346L) and impaired tetramer formation (F502V) as putative diseasemechanisms. All
evaluated KCNT1 variants resulted in marked gain of function with signiﬁcantly increased
channel amplitude and variable blockade by quinidine.
Conclusions
Gain-of-function KCNT1 pathogenic variants cause a spectrum of severe focal epilepsies with
onset in early infancy. Currently, genotype-phenotype correlations are unclear, although clinical
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outcome is poor for themajority of cases. Further elucidation of diseasemechanismsmay facilitate the
development of targeted treatments, much needed for this pharmacoresistant genetic epilepsy.
Glossary
ADNFLE = autosomal dominant nocturnal frontal lobe epilepsy; EIMFS = epilepsy of infancy with migrating focal seizures;
EOEE = early-onset epileptic encephalopathy; NFLE = nocturnal frontal lobe epilepsy; RCK = regulator of potassium
conductance; SLACK = sequence like a calcium-dependent potassium channel; WT = wild-type.
Autosomal dominant pathogenic variants inKCNT1, encoding
the sodium-activated potassium channel, are identiﬁed in
a wide spectrum of epileptic disorders with variable age at
onset and cognitive outcome. These include severe early-onset
epileptic encephalopathies such as Ohtahara and West
syndromes1,2 and epilepsy of infancy with migrating focal
seizures (EIMFS),3–14 as well as autosomal dominant and
sporadic severe nocturnal frontal lobe epilepsies (ADNFLE
and NFLE),10,15,16 but the genotype-phenotype relationship
appears to be unclear. We undertook detailed clinical, molec-
ular genetic, and functional characterization of a cohort of
patients with KCNT1-related epilepsy.
Methods
Patient recruitment
We recruited patients with EIMFS (n = 31) to a research study
investigating the genetic basis of early-onset epileptic en-
cephalopathy (EOEE) between 2011 and 2016, following an
earlier national surveillance study.4 Inclusion criteria were ep-
ilepsywith onset at <2 years and unknown etiology. Diagnostic
criteria for EIMFS were as described in the previous study.4
Patients were recruited at Great Ormond Street Hospital,
London, UK, and by referral from other centers in the United
Kingdom and internationally. Two patients who had routine
local diagnostic multiple gene panel testing revealing KCNT1
variants were also included.
Standard protocol approvals, registrations,
and patient consents
We obtained written informed consent from families in
whom research genetic investigations were undertaken. The
study was approved by the National Research Ethics Service
(London-Bloomsbury, Research Ethics Committee reference
13/LO/0168, Integrated Research Application System project
identiﬁer 95005).We collected anonymized data from patients
tested on the diagnostic next-generation sequencing panel (n =
3) as part of an approved case note review project (Great
Ormond Street Hospital Research and Development De-
partment, 16NM11).
Genetic testing
We used a variety of diﬀerent methods (table e-1, http://links.
lww.com/WNL/A6), including direct Sanger sequencing,
multiple gene panel testingwith the TruSeqCustomAmplicon
panel and SureSelect panel, exome sequencing (e-Methods,
http://links.lww.com/WNL/A8; tables e-1 and e-2, http://
links.lww.com/WNL/A6), and diagnostic chromosomal
microarray.
Homology modeling
HMMscan17 against Pfam (database of sequence-based do-
main families)18 identiﬁed 2 domains in the sequence of hu-
man KCNT1 (isoform 1): ion channel (PF07885, at position
278–346) and calcium-activated BK potassium channel alpha-
subunit family (PF03493, at position 495–598) (e-Methods).
Electrophysiologic assessment of mutant
KCNT1 in xenopus oocyte model
We introduced variants into a wild-type (WT) humanKCNT1
expression construct19 using QuikChange Lightning Site-
Directed Mutagenesis Kit (Agilent Technologies, Santa Clara,
CA). cDNAs were transcribed in vitro (mMessage mMachine;
Ambion, Austin, TX). Oocytes were prepared, and 2-electrode
voltage clamp recording was performed after 14 to 24 hours of
expression. We also recorded currents before and after the
application of Quinidine (e-Methods).
Results
Clinical and molecular genetic features of
KCNT1mutation–positive patients
Clinical presentation
We identiﬁed pathogenic variants in KCNT1 in 12 patients, 5
through direct Sanger sequencing, 2 from whole-exome se-
quencing, and 5 from the Great Ormond Street Hospital di-
agnostic panel (5 of 800 tested patients with EOEE/
developmental delay).
Clinical features are summarized in table 1. Median age at
seizure onset was 3.5 weeks (range 1 day–6 months). Most
patients developed seizures consistent with EIMFS. Two
patients (patients 3 and 11) presented with severe, early-onset
NFLE, characterized by asymmetric tonic posturing and later
fencing posture. We noted similar frontal seizure semiology in
patients with EIMFS (e.g., patient 12). All patients developed
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Table 1 Clinical and genetic features for 12 patients with KCNT1 mutations
Patient
CDS/
protein
change Inheritance
Dx
methods ECS
Age
at
onset Initial seizure type
Subsequent
seizure types
Autonomic
features
MD (age at
onset)
Additional
features
Best
developmental
stage attained
Best response
to treatment
Previous functional
validation?
1a c.811G>T,
V271F
Unknown
(parental
DNA not
available)
WES, SS EIMFS 2 wk HV, eye jerking, oral
automatisms, FM upper
limbs
Asymmetric tonic
posturing, My,
GTCS
Facial
flushing
— — No developmental
milestones
achieved
None Gain of function4,28
2 c.820C>A,
L274I
De novo SS, NGSP EIMFS 1 d HV, ED and jerking, TS
upper limbs
FM seizures of
face and arm
— — — No developmental
milestones
achieved
None
(including
quinidine)
No
3 c.862G>A,
G288S
De novo NGSP NFLE 6 mo Predominantly nocturnal,
asymmetric tonic
posturing
ED, choking
noises, fencing
posture, brief
generalized TS
and GTCS
Facial
flushing
— Right-sided
neglect,
increased tone
on right side,
peripheral
hyperreflexia in
lower limbs
Grasps objects and
standing briefly at
2.5 y, vocalizing and
babbling
None resulted
in seizure
freedom
Gain of
function5,8–10,13,26,28,33
4 c.1038C>G,
F346L
De novo SS EIMFS 7 wk Exaggerated startle, reflex
warm water clonic/My,
evolved to HV and ED,
tonic posturing upper
limbs, FM all limbs
Rapid alternating
ED, facial
grimacing leading
to airway
obstruction
Drooling,
salivation,
apneas
HK MD
affecting
upper limbs
(18 mo)
Coarse facial
features, gum
hypertrophy
Normal
development until
10 wk, then
regression with loss
of social smile and
head control
None No
5 c.1504T>G,
F502V
Maternal
inheritance,
likely
somatic
mosaicism
SS EIMFS 3 mo Behavioural arrest,
staring, upward eye
rolling, HV and ED to either
side, asymmetric tonic
posturing and elevation of
limbs
Flexor spasms
involving the
trunk, clonic
seizures of limbs,
eyelid twitching,
gelastic seizures
HK MD
disorder
involving
head and all
limbs (18
mo)
Cleft of hard
palate
Early social smile
and visual
interaction, lost
after onset of
epilepsy
KD with
vigabatrin,
effect later lost
Quinidine-
marked
reduction in
seizures
No
6 c.2687T>A,
M896K
De novo NGSP EIMFS 2 wk Brief FM all limbs
(twitching)
HV, dystonic
posturing upper
limbs, ED and
jerking
Facial
flushing,
noisy
breathing
HK
movement
perioral
muscles,
tongue,
hand, and
wrists (2 y)
Systemic
proliferative
vasculopathy of
pulmonary and
mediastinal
vessels
No developmental
milestones
achieved
None
(including
quinidine)
No
7 c.2849G>A,
R950Q
Paternally
inherited
SS EIMFS 5 mo HV, TS TS, gelastic
seizures
— HK MD (14
mo)
— Normal until
seizure onset,
(smile and head
control), regression
at 5 mo with no
further
development
None No9
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Table 1 Clinical and genetic features for 12 patients with KCNT1 mutations (continued)
Patient
CDS/
protein
change Inheritance
Dx
methods ECS
Age
at
onset Initial seizure type
Subsequent
seizure types
Autonomic
features
MD (age at
onset)
Additional
features
Best
developmental
stage attained
Best response
to treatment
Previous functional
validation?
8 c.2800G>A,
A934T
De novo SS EIMFS 4 wk HV, ED, fisting of hands Asymmetric tonic
posturing, ED, oral
9 automatisms
Facial
flushing
Limb
dystonia
and severe
scoliosis (18
mo)
Peripheral
hypertonia
Babbling, some
degree of head
control
Steroids and
KD in
combination
at 7–12 mo
Gain of
function3,4,8,9,20
9a c.2800G>A,
A934T
De novo WES EIMFS 2 wk HV, ED, vocalization T10S with
adversive
component
Facial
flushing,
pupillary
dilation
— Gastrointestinal
dysmotility
Partial head control,
smiling
Nitrazepam at
5 mo
10 c.2800G>A,
A934T
De novo NGSP EIMFS 3 wk HV, ED with pupil jerking,
FM arm and face, oral
automatisms
HV, ED, drooling,
TS with adversive
component, FM
upper limbs
Facial
flushing
— — Smiling, visual
awareness, some
head control, rolling
Stiripentol,
levetiracetam,
and
clonazepam in
combination
11 c.2800G>A,
A934T
De novo NGSP NFLE 8 wk Focal motor seizures
hands, ED and jerking, TS
upper limb and FM
contralateral lower limb
Seizures only in sleep
Stopped at 4–5 mo
From 11 mo: TS
with fist clenching,
ED, asymmetric
tonic posturing,
mainly from sleep
— — Right-sided
weakness with
peripheral
hyperreflexia
Walking before
regression at 11mo,
best subsequent
stage sitting
independently
No sustained
response
12 c.2800G>A,
A934T
De novo NGSP EIMFS 3 wk ED with eye flickering, HV,
TS upper limbs
FM upper and
lower limbs with
lip smacking,
hand fisting, HV
and ED, fencing
posture of arm
Facial
flushing
— — Social smile and
reaching for objects
until regression and
loss of these skills at
5 mo
KD and
lacosamide in
combination
Abbreviations: CDS = coding sequence; Dx = diagnostic; ECS = electroclinical syndrome; ED = eye deviation; EIMFS = epilepsy of infancy with migrating focal seizures; FM = focal motor; GTCS = generalized tonic-clonic seizures;
HK = hyperkinetic; HV = head version; KD = ketogenic diet; MD =movement disorder; My =myoclonic seizures; NFLE = nocturnal frontal lobe epilepsy; NGSP = next-generation sequencing panel; SS = Sanger sequencing; TS =
tonic seizures.
a Previously described by McTague et al.4
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axial hypotonia, and upper motor neuron signs emerged in 3
patients. Four patients had a choreiform movement disorder
(onset 14–24 months); 1 patient developed generalized dys-
tonia at 18 months. Onset of hyperkinesia was not related to
medication (including vigabatrin) nor triggered by in-
tercurrent illness. Initial age at presentation, disease course,
response to medication, brain MRI, and EEG ﬁndings were
similar for both KCNT1 pathogenic variant–positive and –
negative patients from the cohort.However, 5 of 12 pathogenic
variant–positive patients with EIFMS presented with a severe
movement disorder compared to 2 of 19 KCNT1-negative
cases. Most had extensive uninformative laboratory metabolic
and genetic investigations. Abnormal muscle respiratory chain
enzyme activity for complex I and/or II was detected in
patients 4 and 8 of uncertain signiﬁcance (table e-3, http://
links.lww.com/WNL/A6). For patient 4, the muscle biopsy
was taken during an intercurrent illness and repeated after
clinical recovery, revealing a more borderline result. In patient
8, borderline abnormalities in complex I and II ratios were
found. Neither patient had other systemic, biochemical, or
radiologic features of mitochondrial disease or concurrent
sodium valproate treatment.
In general, neurodevelopmental outcome was markedly im-
paired in all patients with EIMFS. All patients had a trial of at
least 5 diﬀerent medications. Response to treatment was, in
general, poor (table 1). Three of 8 patients who received the
ketogenic diet in combination with other antiepileptic drugs
responded with ≈75% seizure reduction. Three patients were
treated with quinidine. Patient 2 received 40 mg/kg/d without
adverse events but with no eﬀect on seizure burden. Patient 5
was treated with quinidine at 40 mg/kg/d, leading to a marked
reduction in seizure frequency. Patient 6 showed some initial
transient reduction in seizure frequency at 30 mg/kg/d. For
this patient, the unexpected development of a severe pro-
liferative pulmonary and mediastinal vasculopathy resulted in
life-threatening pulmonary hemorrhage. Investigations failed
to identify an underlying vasculitis, and quinidine was sub-
sequently withdrawn. The patient later died despite initial
successful pulmonary embolization.
EEG features
All patients with an EIMFS phenotype had a “migrating” ictal
focus with discrete ictal involvement of diﬀering cortical areas
within the same EEG (table e-4, http://links.lww.com/WNL/
A6). Although not always evident at initial presentation, it
developed by 7months of age inmost patients. Periods of EEG
suppression or burst suppression were noted in 8 of 12
patients; 6 of these patients had seizure onset in the ﬁrst 4
weeks of life. Further atypical EEG features included a gener-
alized electrodecremental response in 5 patients and hypsar-
rhythmia in 1 patient.
Radiologic features
Neuroimaging was available for review in 11 of 12 patients. The
majority developed predominantly frontal cerebral atrophy by 3
years of age (ﬁgures e-1A and e-1B, http://links.lww.com/
WNL/A7; table e-5, http://links.lww.com/WNL/A6). Cere-
bellar atrophy was also evident in 4 patients (ﬁgure e-1C).
We noted an open operculum in the ﬁrst 6 months of life in
patient 4 (ﬁgure e-1B). Delayed myelination was evident in
9 of 11 patients who had imaging after 3 months of age. In
some patients, early brain imaging was normal. Magnetic
resonance spectroscopy was abnormal with a relatively
reduced N-acetylcholine peak in 3 of 4 patients.
Molecular genetic findings
We identiﬁed 12 patients with pathogenic variants in KCNT1
(table 1 and table e-6, http://links.lww.com/WNL/A6); 8
have been previously reported and 4 are unpublished.4,5,9,10,16
Eight of 12 patients had C-terminus variants, of whom 5 had
the commonly reported variant A934T. We have identiﬁed 4
(including 2 unpublished) pathogenic variants causing EIMFS,
namely V271F, L274I, G288S, and F346L located in or be-
tween transmembranes 5 and 6. All are missense variants that
are predicted to be pathogenic (table e-6), aﬀecting highly
conserved amino acid residues (ﬁgure e-2, http://links.lww.
com/WNL/A7), and are not reported in 1000 Genomes, the
ExAC database, or the Exome Variant Server.20–24 For 9 of 12
cases, variants occurred de novo. Parental DNA was not
available for patient 1. In patient 5, we found the sameKCNT1
variant in an asymptomatic mother and her aﬀected child. We
noted a lower heterozygous peak on Sanger sequencing of both
salivary and blood-derived maternal genomic DNA (ﬁgure
e-3), which may reﬂect somatic mosaicism. In patient 7, the
variant was inherited from the unaﬀected father with no dif-
ference in peak size on Sanger sequencing (ﬁgure e-4). The
recurrent A934T variant was identiﬁed in 5 patients, 4 with an
EIMFSpresentation and 1 (patient 11)with anNFLEphenotype.
Protein homology modeling of mutant KCNT1
Homology modeling was performed for 2 novel mutations:
F346L, located in the ion channel domain (residues 270–353),
and F502V, located in the gating region (residues 373–1174,
although residues 1,045–1,174 could not be modeled). F346 is
located on the inner helix of the transmembrane pore (ﬁgure 1,
A and B). It is part of the hydrophobic cavity, which mediates
interactions between the inner-membrane helices of 2 adjacent
subunits (ﬁgure 1C) and is thus responsible for maintaining the
stability of the open conformation. In themodeled closed-state
conformation, the helix containing F346 and the inner helix
from the other protomer undergo conformational changes
(ﬁgure e-5, http://links.lww.com/WNL/A7). Therefore, mu-
tation to leucine (F346L) is likely to destabilize the open state
by perturbing the hydrophobic interactions because the side
chain of leucine is smaller (ﬁgure 1D), aﬀecting the equilibrium
between the closed and open states. In addition, the packing
arrangement in the K+ channels involving the pore and the
inner helix is known to be critical for the stability of the tet-
rameric assembly, ion conduction function, and cation selec-
tivity. Thus, F346L might be detrimental to these functions.25
Within each protomer of the KCNT1 gating region, there are 2
tandem RCK domains (RCK1 and RCK2) that serve as
Neurology.org/N Neurology | Volume 90, Number 1 | January 2, 2018 e5
Figure 1 Modeling the ion channel and gating apparatus of KCNT1
(A) Side view of the homologymodel of the KCNT1 ion channel (residues 278–346) as a tetramer. F346 is present on the edge of the inner helix (in gold) and interacts
with the inner helix of the adjacent subunit in the tetrameric arrangement. Membrane position is shown in spheres. (B) Top view of the tetramer arrangement of the
ion channel and location of F346 on the inner helix. (C) F346 is part of the hydrophobic cavity (shown as surface), which mediates interactions between the inner
membranehelices of the 2 subunits. F346 is shown in green; the surrounding hydrophobic residues are shown in red. (D)Onmutation to leucine (F346L, in green), the
hydrophobic interactions between the2 subunits are likely tobe reduced (black circle) because the side chain of leucine ismuch shorter thanphenylalanine. (E)Model
of a dimer of the gating ring (residues 373–1,044; residues 1,045–1,174 could not be modeled), which is a tetramer (dimer of the modeled dimer). Each subunit
possesses 2 RCK domains: RCK1 (in blue) and RCK2 (in gold). F502 (in green) is present in the RCK1 domain, near the intersubunit interface (assembly interface). The
RCK1-RCK2 intrasubunit interface ispurple (residues fromRCK1)andorange (residues fromRCK2). Thedimer interfaces formedbybothRCK-1andRCK-2are indicated
by anarrow. (F) F502 (green) and its neighboring hydrophobic residues (red), includingW476,withwhich it could potentially formapi-pi interaction. Distance between
the centroid (spheres) of the 2 rings (F502andW476) is 4.7 A˚, and theanglebetween the ringplanes is 27.3°. (G) F502V could abolish the formationof thepotential pi-pi
interaction with W476 and is likely to reduce the hydrophobic interactions (black circle) because the side chain of valine is smaller than that of phenylalanine.
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regulators of potassium conductance (ﬁgure 1E). These form
ﬂexible intrasubunit and intersubunit (ﬁgure 1E) interfaces
that facilitate functional tetramer formation.26 F502 is located
in RCK1 and predicted to form a pi-pi interaction with W476
from αD (ﬁgure 1F). F502 is also surrounded by a number of
hydrophobic residues (I472, L473, A475, V500, and A503),
which may play a role in stabilizing the gating ring (ﬁgure 1F).
The amino acid substitution F502V is predicted to result in
destabilization of these hydrophobic interactions, given the
smaller valine side chain (ﬁgure 1G), and abolition of potential
pi-stacking with resultant disruption of the stable assembly
interface.
Electrophysiologic assessment of
mutant KCNT1
We evaluated the 4 previously unpublished variants and
V271F, which we previously described4 and was recently
studied in a xenopus oocyte system.27 All mutations resulted in
an increased current magnitude compared to WT (ﬁgure 2A).
We noted that for variants V271F and F346L, the rate of
activation was slowed at higher voltages compared toWT, and
in others (M896K, F502V and L274I), the activation rates
were generally faster thanWT (ﬁgure 2A). Investigation of the
current-voltage relationship showed that mutant channels
were very weakly voltage dependent, and in some cases, voltage
dependence of steady-state activation was essentially absent
(ﬁgure 2, B and C) with only a residual Goldman-Hodgkin-
Katz rectiﬁcation. Assessment of average peak currents at 10
mV revealed a signiﬁcant diﬀerence between both individual
mutant channels and summated data compared to WT (ﬁgure
2, D and E).
Effect of 300 μmol/L quinidine on
mutant KCNT1
Quinidine 300 μmol/L had variable current-blocking eﬀects in
diﬀerent mutant channels. For F346L, peak current was
completely insensitive to quinidine, although it had some eﬀect
on activation kinetics (ﬁgure 3A). The diﬀerential sensitivity of
KCNT1 mutants to quinidine was clearly shown in the
current-voltage relationship (ﬁgure 3B) and percentage of in-
hibition at maximum current, 80 mV (ﬁgure 3C). There is
some correlation between the in vitro studies and clinical re-
sponse in patient 5 (ﬁgure 3). M896K had the most marked in
vitro blockade by quinidine, and patient 6 showed some initial
clinical response. F346L showed no quinidine response at all,
and the patient harboring this mutation was not treated with
quinidine.
Discussion
We report a cohort of patients with early-onset epilepsy as-
sociated with pathogenic variants in KCNT1, which encodes
the sodium-activated potassium channel KCa4.1 (sequence
like a calcium-dependent potassium channel [SLACK],
Slo2.2). KCNT1 is widely expressed throughout the brain, as
well as in the dorsal root ganglia, kidney, and heart, and is
responsible for slow hyperpolarization after bursts of action
potentials.28,29 KCNT1 also has direct interactions with Fragile
X-related protein.29 Compared with other potassium channels,
KCNT1 is involved in a highly extensive protein network,
suggesting a putative role in cognitive developmental
processes.3,8,28,30
To date, KCNT1 variants have been reported in a wide range
of epilepsies (table e-7, http://links.lww.com/WNL/
A6).1–16,31,32 We identiﬁed patients with the same variant as-
sociated with varying electroclinical phenotypes (table 1).
Phenotypic variability has been reported within single families
in which diﬀerent individuals may present with either
ADNFLE or EIMFS.10 Such intrafamilial variation in pheno-
type is also described in SCN1A kindreds; Dravet syndrome,
febrile seizures, and a variety of other generalized epilepsies
may be reported in the same family.33 Furthermore, while
the majority of variants in our cohort occurred de novo, 2
patients inherited variants from an unaﬀected parent. The
mechanisms underlying phenotypic variability and true/apparent
nonpenetrance are unclear but may be related to somatic mosa-
icism, variant type, other genetic/epigenetic factors, or diﬀerential
expression of alternative KCNT1 transcripts.9,10,29,34,35
The majority of patients with pathogenic KCNT1 variants in
our cohort had electroclinical EIFMS, although this is likely to
reﬂect ascertainment bias. Indeed, 2 of the 5 KCNT1-positive
patients identiﬁed by the diagnostic panel from a larger cohort
of 800 patients with EOEE/developmental delay had an
NFLE-like presentation. Although movement disorders are
increasingly reported in other severe early-onset genetic
epilepsies, they appear to be rare in KCNT1 epilepsy.36 We
describe several atypical EEG features. Generalized electro-
decrement and hypsarrhythmia, more classically associated
with infantile spasms, have been previously described in
EIMFS.2,4,9,10,31 EEG suppression, classically seen in Ohtahara
syndrome,37 has been only rarely described in EIMFS.4,9 Ex-
tensive diagnostic investigations undertaken in patients with
KCNT1 mutations were unyielding other than abnormal re-
spiratory chain enzyme analysis of muscle tissue in 2 patients.
The relevance of these ﬁndings is not clear, but secondary
mitochondrial eﬀects may be evident in KCNT1 epilepsy, as
often reported in other severe drug-resistant epilepsies.38
Other genetic and environmental inﬂuences on mitochondrial
function may also play a role.
KCNT1 tetramers form a transmembrane sodium-activated
potassium channel. Each subunit consists of 6 transmembrane
domains with an extended cytoplasmic carboxy (C-) terminus
(ﬁgure 4). The majority of reported pathogenic variants (table
e-7, http://links.lww.com/WNL/A6), as seen in this study, are
located in the C-terminus with clustering around the RCK and
nicotinamide adenine dinucleotide–binding domains (ﬁgure
4). More recently, several variants have been identiﬁed within
transmembrane domain 5 and in the pore-forming regions
between transmembrane domains 4 and 54,5,8–10 (table e-7),
and this study also demonstrates epilepsy-associatedmutations
in transmembrane domains.
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To date, diﬀerent model systems have been used to determine
the functional eﬀects of KCNT1 variants.1,5,7,10,13,19,27 Our pro-
tein homology structural modeling data predict abnormal
gating or protein instability within the pore-forming region as
a putative disease mechanism. In silico modeling of G288S has
predicted similar detrimental eﬀects,5 while Y775H is pre-
dicted to aﬀect sodium sensitivity of the channel.27 KCNT1
variants may therefore alter structural properties of the protein,
contributing to altered channel function. Consistent with
previous reports1,3,13,19,27 (table e-7, http://links.lww.com/
WNL/A6), our xenopus oocyte model demonstrated that
KCNT1 pathogenic variants display a gain-of-function eﬀect
with increased current amplitude (ﬁgure 2). Previous studies
have sought to correlate disease severity with the degree of gain
of function.1,19 However, in keeping with more recent studies,8
such correlation was not evident in our study. KCNT1 variants
result in an increased Po (probability of the channel being
open), which may be due to increased mutant channel coop-
erativity or altered sodium sensitivity.8,27 In a recent study,
sodium removal from the pipette solution had a less negative
eﬀect on G288S channel amplitude than WT, suggesting
reduced sodium sensitivity in the mutant.13 Heterotetramer
formation may be of importance in vivo. In 1 study, mutant
KCNT1 homomers revealed a more marked gain of function
than mutant WT heteromers.13 A signiﬁcant remaining
question is how KCNT1 gain-of-function variants with pre-
dicted eﬀects on neuronal hyperpolarization result in epi-
lepsy.28 Altered voltage sensitivity may result in KCNT1
Figure 2 Functional investigation of KCNT1 mutations in a xenopus oocyte model
(A) Representative current traces obtained from oocytes expressing WT and EIMFS mutants (M896K, F502V, V271F, F346L, and L274I). Oocytes were held at
−90 mV and stepped from −80 to 80 mV for 600 milliseconds every 5 seconds. Scale bars apply to all traces. (B) Current-voltage relationships for WT (n = 32),
M896K (n = 15), F502V (n = 13), V271F (n = 9), F346L (n = 11), and L274I (n = 12). Currents were averaged and then normalized to the value at a test potential of
80 mV (Imax). (C) Comparison of current-voltage relationships between WT (solid circles, n = 32) and EIMFS mutations (M896K [squares, n = 15], F502V
[triangles, n = 13], V271F [hexagons, n = 9], F346L [diamonds, n = 11], and L274I [inverted triangles, n = 12]). Currents were averaged and then normalized to
the value at a test potential of 80mV (Imax). (D) Average peak currents at 10 mV for WT (n = 44), M896K (n = 19), F502V (n = 16), V271F (n = 10), F346L (n = 11),
and L274I (n = 12) channels. Peak currents for eachmutant channel at 10mVwere compared to the peak currents for theWT channel at 10mV. ***p < 0.001,
****p < 0.0001. (E) Comparison of pooled WT (n = 44) and EIMFS (n = 68) currents at 10 mV. ****p < 0.0001. EIMFS = epilepsy of infancy with migrating focal
seizures; WT = wild-type.
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channels opening at more depolarized potentials, allowing
a persistent hyperpolarizing current, with resultant in-
terneuronal disinhibition as reported in SCN1A-related ep-
ilepsy.39 Conversely, increased repolarization permitting more
frequent and rapid action potentials may also play a role.27,34
Recently, quinidine has been identiﬁed as a novel therapy
for patients with KCNT1-related epilepsy. In in vitro models,
quinidine has been shown to reduce the abnormal increase in
mutant KCNT1 channel amplitude.19 For 1 patient with
EIMFS with the KCNT1 variant R428Q , in vitro testing
showed quinidine sensitivity, and treatment resulted in a dra-
matic improvement in seizure control with neuro-
developmental gains.3,7 However, in more recent studies,
patient response has been variable and not always as predicted
by in vitro studies.11 Indeed, another patient with the same
variant (R428Q) but diﬀerent epilepsy phenotype (un-
classiﬁed EOEE) failed to respond to quinidine, albeit at a later
stage in the disease course.14 Most recently, a patient with
West syndrome had a good response but only with a higher
dose of 60 mg/kg/d.2 Clinical response may possibly be de-
termined by the speciﬁc variant, other genetic factors, epilepsy
phenotype, and drug timing within a therapeutic window. In
our series, we treated 3 patients with quinidine, and 1 patient
showed a clinical response. One patient developed a severe
pulmonary vasculopathy, after which quinidine was dis-
continued. Systemic vasculitis has been reported with quinidine
treatment.40 While investigations in our patient did not reveal
overt evidence of vasculitis, the observed pulmonary dys-
function may represent an adverse drug-related event. The
precise mechanism of KCNT1 blockade by quinidine is un-
clear, and it is possible that the disease mechanism for F346L,
Figure 3 Effect of quinidine on xenopus oocytes expressing hKCNT1 channels
(A) Representative current traces obtained from oocytes expressing WT and EIMFS mutants (M896K and F346L) with application of vehicle (ND96) and 300
μmol/L quinidine. Oocyteswere held at−90mVand stepped from −80 to 80mV for 600milliseconds every 5 seconds. Scale bars apply to all traces. (B) Current-
voltage relationships forWT (n = 32), M896K (n = 15), F502V (n = 13), V271F (n = 9), F346L (n = 11), and L274I (n = 12) hKCNT1 channels in the presence of vehicle
(ND96) and 300μmol/L quinidine. Currentswere averagedand then normalized to the value at a test potential of 80mV (Imax). (C) Average percent inhibition at
80 mV of WT (n = 31) and EIMFS (M896K, n = 15; F502V, n = 13; V271F, n = 9; F346L, n = 11; and; L274I, n = 12) hKCNT1 channels by quinidine (300 μmol/L)
depicting the variable degree of block by 300μmol/L quinidine (1-way analysis of variance followed by Bonferroni post hoc analysis). *p < 0.1. EIMFS = epilepsy
of infancy with migrating focal seizures; WT = wild-type.
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perhaps involving abnormal channel-opening dynamics as sug-
gested by the modeling data, is not modiﬁable by quinidine. Our
data suggest that quinidine should be considered as a therapeutic
option for patients withKCNT1 variants, but used with caution.
Larger studies will provide further guidance about clinical
utility, patient selection, optimum age at administration, and
dose. Other KCNT1 modulators, including bepridil and clo-
ﬁlilum, have been identiﬁed as possible alternative therapies.28
Like quinidine, bepridil has been shown in vitro to reversibly
block mutant KCNT1 channels at a lower concentration than
WT channels.13 However, similar to quinidine, potential car-
diac eﬀects and lack of speciﬁcity may limit use in patients.
Pathogenic variants inKCNT1 cause a wide spectrumof severe
epilepsies typically associated with impaired neurologic
development and signiﬁcant disease burden. As demonstrated,
in vitromodel systemsmay be useful to validate putative variants
and to conﬁrm pathogenicity, although genotype-phenotype
correlations remain unclear. Evaluation of new therapies, in-
cluding KCNT1-speciﬁc blockers, remains a research priority
for this devastating pharmacoresistant group of epilepsies.
Note added in proof
Recently, 3 patients with de novo KCNT1 mutations and
massive systemic to pulmonary collateral artery formation,
presenting with pulmonary hemorrhage requiring emboliza-
tion, were described. These patients had not been treated with
quinidine. However, the mechanism remains unclear and fur-
ther investigation of the expression and role of KCNT1 in the
cardiovascular system is required.41
Figure 4 Schematic diagram of the location of mutations in KCNT1 in this and previously published studies
KCNT1 encodes sequence like a calcium-dependent potassium channel (SLACK), which forms tetramers (top left) or heteromers with KCNT2 or sequence like an
intermediate conductance K channel (SLICK). The structure comprises 6 transmembrane domains with a pore-forming region, regulator of potassium conductance
(RCK), and nicotinamide adenine dinucleotide–binding (NAD-B) domains. EIMFS phenotypes are shaded in purple, ADNFLE or NFLE in pink, others (Ohtahara
syndrome, leukoencephalopathy, focal epilepsy, EOEE,West syndrome,unaffected) inorange.Mutationsgiving rise to>1phenotypeareshadedwitha combinationof
the corresponding colors. Novel mutations identified in this study are outlined in green, those identified in previous studies in turquoise. ADNFLE = autosomal
dominant nocturnal frontal lobe epilepsy; EIMFS = epilepsy of infancy with migrating focal seizures; EOEE = early-onset epileptic encephalopathy; NFLE = nocturnal
frontal lobe epilepsy.
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